Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
06:30am, Tuesday, 06'th Aug 2024
U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa)
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
08:45am, Friday, 26'th Jul 2024
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
08:23am, Wednesday, 24'th Jul 2024
Speculators seeking a big pop over the next few months should consider a high-risk, high-reward position in Beam Therapeutics (NASDAQ: BEAM ). According to its public profile, Beam specializes in prec
3 Gene Editing Stocks Shaping the Future of Medicine
04:45pm, Monday, 22'nd Jul 2024
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby ope
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
11:16am, Tuesday, 16'th Jul 2024
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
02:01pm, Thursday, 11'th Jul 2024
Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 09'th Jul 2024
Beam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
07:00am, Tuesday, 09'th Jul 2024
Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for underval
3 Stocks With the Potential to 10X Your Money
06:25am, Tuesday, 09'th Jul 2024
In recent months, markets have reached new record highs, signaling that high-growth potential stocks offer opportunities to multiply earnings. The number of high-wealth individuals in the U.S. grew su
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
02:13pm, Thursday, 04'th Jul 2024
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare envir
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
09:12am, Wednesday, 03'rd Jul 2024
Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division.
You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
10:02pm, Thursday, 27'th Jun 2024
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the b
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
11:30am, Thursday, 27'th Jun 2024
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
06:30am, Wednesday, 26'th Jun 2024
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the firs
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting i
